FDCC
NVO

Foster Dykema Cabot & Co’s Novo Nordisk NVO Stock Holding History

Foster Dykema Cabot & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$281K Hold
3,090
– – 0.03% 74
2023
Q2 		$250K Buy
+3,090
New +$252K 0.03% 84

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Foster Dykema Cabot & Co's NVO Position: Q3 2023 in Review

Foster Dykema Cabot & Co held its Novo Nordisk (NVO) position steady in Q3 2023 at 3,090 shares worth $281K. The position accounts for 0.03% of the portfolio, ranked #74.

Foster Dykema Cabot & Co first reported a position in NVO in Q2 2023 and has held it in 2 quarters since. 1,307 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • Foster Dykema Cabot & Co held 3,090 shares of Novo Nordisk worth $281K as of Q3 2023.
  • Foster Dykema Cabot & Co left its Novo Nordisk share count unchanged in Q3 2023.
  • Novo Nordisk made up 0.03% of Foster Dykema Cabot & Co's portfolio in Q3 2023, its #74 holding.
  • Foster Dykema Cabot & Co first reported a position in Novo Nordisk in Q2 2023 and has held it in 2 quarters since.
  • 1,307 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.